155020-51-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzenamine, 2,3-difluoro-4-methoxy(9CI) is used as an intermediate in the synthesis of various pharmaceutical compounds for its unique structural properties. The presence of fluorine and methoxy groups can influence the compound's reactivity, stability, and biological activity, making it a valuable building block in the development of new drugs.
Used in Chemical Research:
In the field of chemical research, Benzenamine, 2,3-difluoro-4-methoxy(9CI) serves as a model compound for studying the effects of fluorination and methoxylation on the chemical and physical properties of aromatic amines. Its unique structure allows researchers to investigate the influence of electron-withdrawing fluorine atoms and electron-donating methoxy groups on the reactivity, stability, and spectroscopic properties of the molecule.
Used in Dye Production:
Benzenamine, 2,3-difluoro-4-methoxy(9CI) can be used as a precursor in the synthesis of novel dyes with improved properties, such as enhanced color intensity, stability, and solubility. The presence of fluorine and methoxy groups can alter the electronic structure of the dye molecules, leading to changes in their absorption and emission characteristics.
Used in Material Science:
In material science, Benzenamine, 2,3-difluoro-4-methoxy(9CI) can be employed as a building block for the development of new organic materials with tailored properties. Its unique structure can be utilized to design materials with improved thermal stability, electrical conductivity, or optical properties, depending on the specific application requirements.

InChI:InChI=1/C7H7F2NO/c1-11-5-3-2-4(10)6(8)7(5)9/h2-3H,10H2,1H3

Upstream product

• 771-69-7 2,3,4-trifluoronitrobenzene 
• 66684-59-1 2,3-difluoro-1-methoxy-4-nitrobenzene 

Downstream Products

• 940298-94-2 2,3-difluoro-4-methoxyphenylhydrazine hydrochloride 
• 1138820-03-7 2-fluoro-N-(2,3-difluoro-4-methoxyphenyl)pyridine-3-carboxamide 
• 155020-46-5 3-<(diethylamino)methyl>-5,6-difluoro-4-hydroxyacetanilide 
• 1026596-14-4 4-Amino-2-diethylaminomethyl-3,5-difluoro-phenol 
• 155020-53-4 2,3-difluoro-4-hydroxyacetanilide 
• 155020-52-3 2,3-difluoro-4-methoxyacetanilide 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS

Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

NOVEL ALKYLENE DERIVATIVE

The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

The Effect of Fluorine Substitution on the Metabolism and Antimalarial Activity of Amodiaquine

Amodiaquine (AQ) (2) is a 4-aminoquinoline antimalarial which causes adverse side effects such as agranulocytosis and liver damage.The observed drug toxicity is believed to be related to the formation of an electrophilic metabolite, amodiaquine imine (AQQI), which can bind to cellular macro-molecules and initiate hypersensitivity reactions. 5'-Fluoroamodiaquine (5'-FAQ, 3), 5',6'-difluoroamodiaquine (5',6'-DIFAQ, 4), 2',6'-difluoroamodiaquine (2',6'-DIFAQ, 5), 2',5',6'-trifluoroamodiaquine (2',5',6'-TRIFAQ, 6) and 4'-dehydroxy-4'-fluoroamodiaquine (4'-deOH-4'-FAQ, 7) have been synthesized to assess the effect of fluorine substitution on the oxidation potential, metabolism, and in vitro antimalarial activity of amodiaquine.The oxidation potentials were measured by cyclic voltammetry, and it was observed that substitution at the 2',6'- and 4'-positions (2',6'-DIFAQ and 4'-deOH'4'-FAQ) produced analogues with significantly higher oxidation potentials than the parent drug.Fluorine substitution at the 2',6'-positions and 4'-position also produced analogues that were more resistant to bioactivation.Thus 2',6'-DIFAQ and 4'-deOH-4'-FAQ produced thioether conjugates corresponding to 2.17percent (SD: +/-0.27percent) and 0percent of the dose compared with 11.87percent (SD: +/-1.31percent) of the dose for amodiaquine.In general the fluorinated analogues had similar in vitro antimalarial activity to amodiaquine against the chloroquine resistant K1 strain of Plasmodium falciparum and the chloroquine sensitive T9-96 strain of P. falciparum with the notable exception of 2',5',6'-TRIFAQ (6).The data presented indicate that fluorine substitution at the 2',6'-positions and replacement of the 4'-hydroxyl of amodiaquine with fluorine produces analogues ( 5 and 7) that maintain antimalarial efficacy in vitro and are more resistant to oxidation and hence less likely to form toxic quinone imine metabolites.